"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Opens in a new tab or window While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen ...

Brian Griffin has incurable blood cancer and, while he is well enough at the moment after a second and final stem cell ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

These six high-yield dividend stocks are universally loved by investment professionals and they now offer reasonable entry ...

some of which will potentially be used to accelerate the development of next-generation product candidates targeting multiple ...

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL – Free Report) from a neutral rating to a buy rating in ...

( MENAFN - GlobeNewsWire - Nasdaq) Stem Cell Therapy market Size Was Valued at USD 12.05 Billion in 2023, and is Projected to Reach USD 31.33 Billion by 2032, Growing at a CAGR of 11.20% From ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

Rising incidence of cancer around the world is projected to primarily augment the demand for CAR T-cell therapy (CAR-T (Chimeric Antigen Receptor T-cell) therapy) over the coming years.Westford, USA, ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...